Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co

Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes is a phase 2, randomised interventional study registered as NCT06949982 by Sergey Orlov, MD, with a registry enrolment figure of 60 participants, started 2025-03-17 and due to reach its primary completion in 2027-04. Interventions recorded: experimental group x-MAP; Regorafenib (BAY 73-4506). Conditions listed: Metastatic Colorectal Cancer (mCRC); Colorectal Neoplasms. Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of colorectal cancer (CRC) with distant metastases". Sites: Russia. No results are recorded here; the registry entry is the source.